

WHAT IS CLAIMED IS:

1. A composition for topical application to skin, comprising, in a physiologically acceptable medium, (i) at least one peptide comprising at least one amino acid sequence derived from the amino acid sequence of the protein SNAP 25, and (ii) at least one calcium-channel inhibitor.

2. The composition according to Claim 1, wherein the at least one peptide is the hexapeptide defined by SEQ ID No. 2.

3. The composition according to Claim 1, wherein the at least one peptide is chosen from:

- (i) a peptide that is substantially homologous with the peptide defined by SEQ ID No. 2;
- (ii) a cosmetically acceptable salt of the peptide defined by SEQ ID No. 2; and
- (iii) a peptide defined by SEQ ID No. 2 that has undergone reversible chemical changes.

4. The composition according to Claim 1, wherein the at least one peptide is chosen from:

- a. a peptide comprising a sequence ranging from 3 to 30 amino acids contained in SEQ ID No. 1;
- b. a peptide comprising a sequence ranging from 6 to 19 amino acids derived from the N-terminus of the protein SNAP 25, chosen from the peptides defined by SEQ ID No. 2 and SEQ ID No. 3;
- c. a peptide comprising a sequence ranging from 6 to 19 amino acids derived from the C-terminus of the protein SNAP 25, chosen from the peptides defined by SEQ ID No. 5 and SEQ ID No. 6;

- d. a peptide mixture comprising at least one peptide ranging from 3 to 30 amino acids chosen from those described in a), b) and c) and at least one peptide ranging from 3 to 30 amino acids contained in SEQ ID No. 4; and
- e. a peptide mixture comprising at least one peptide chosen from the peptides defined by SEQ ID No. 2 and SEQ ID No. 3 and at least one peptide chosen from the peptides defined by SEQ ID No. 5 and SEQ ID No. 6.

5. The composition according to Claim 1, wherein the at least one calcium-channel inhibitor is chosen from alverine and salts thereof, manganese and salts thereof, and magnesium and salts thereof.

6. The composition according to Claim 5, wherein the at least one calcium-channel inhibitor is magnesium gluconate.

7. The composition according to Claim 1, comprising at least the hexapeptide defined by the sequence SEQ ID No. 2 and at least magnesium gluconate.

8. The composition according to Claim 1, wherein the at least one peptide is present in an amount ranging from 0.000001% to 1% by weight of the total weight of the composition.

9. The composition according to Claim 8, wherein the at least one peptide is present in an amount ranging from 0.00001% to 0.01% by weight of the total weight of the composition.

10. The composition according to Claim 1, wherein the at least one calcium-channel inhibitor is present in an amount ranging from 0.0001% to 10% by weight of the total weight of the composition.

11. The composition according to Claim 10, wherein the at least one calcium-channel inhibitor is present in an amount ranging from 0.01% to 1% by weight of the total weight of the composition.

12. The composition according to Claim 1, further comprising at least one active agent chosen from desquamating agents; moisturizers; depigmenting and propigmenting agents; anti-glycation agents; NO-synthase inhibitors; agents for stimulating the synthesis of dermal or epidermal macromolecules and/or for preventing their degradation; agents for stimulating fibroblast and/or keratinocyte proliferation or for stimulating keratinocyte differentiation; dermo-relaxants; tightening agents; antipollution agents and free-radical scavengers; agents that act on the capillary circulation; and agents that act on the energy metabolism of cells.

13. The composition according to Claim 1, further comprising at least one adjuvant chosen from hydrophilic and lipophilic gelling agents, hydrophilic and lipophilic active agents, preserving agents, antioxidants, solvents, fragrances, fillers, screening agents, pigments, odor absorbers and dyestuffs.

14. The composition according to Claim 13, wherein the at least one adjuvant is present in an amount ranging from 0.01% to 20% by weight of the total weight of the composition.

15. The composition according to Claim 1, wherein the composition is in a form chosen from an optionally gelled aqueous solution, a lotion dispersion, optionally a two-phase lotion, an O/W emulsion, an W/O emulsion, a triple emulsion chosen from W/O/W and O/W/O emulsions, and ionic and nonionic vesicular dispersions.

16. The composition according to Claim 15, wherein the composition is in a form of an O/W emulsion.

17. The composition according to Claim 1, further comprising at least one photoprotective agent chosen from UVA-active and UVB-active organic and mineral photoprotective agents.

18. The composition according to Claim 17, wherein the at least one photoprotective agent is present in an amount ranging from 0.1% to 20% by weight of the total weight of the composition.

19. A method of making a cosmetic composition for topical application to skin, comprising including in the composition, as an agent for preventing or treating wrinkles and fine lines, (i) at least one peptide comprising at least one amino acid sequence derived from the amino acid sequence of the protein SNAP 25, and (ii) at least one calcium-channel inhibitor.

20. The method according to Claim 19, wherein the prevention or treatment of wrinkles and fine lines comprises smoothing out the wrinkles and fine lines.

21. The method according to Claim 19, wherein the wrinkles are expression wrinkles.

22. A cosmetic process for preventing wrinkles and fine lines on skin, comprising topically applying a composition to the skin, wherein the composition comprises, in a physiologically acceptable medium, (i) at least one peptide comprising at least one amino acid sequence derived from the amino acid sequence of the protein SNAP 25, and (ii) at least one calcium-channel inhibitor.

23. The cosmetic process according to Claim 22, wherein the wrinkles are expression wrinkles.

24. A cosmetic process for treating wrinkled skin, comprising topically applying a composition to the skin, wherein the composition comprises, in a physiologically acceptable medium, (i) at least one peptide comprising at least one amino acid sequence derived from the amino acid sequence of the protein SNAP 25, and (ii) at least one calcium-channel inhibitor.

25. The process according to Claim 24, wherein said composition is applied to the areas of the face or forehead marked with expression wrinkles and fine lines and/or to individuals with expression wrinkles and fine lines.

26. The process according to Claim 24, wherein said composition is applied to the wrinkles and fine lines lying radially around the mouth and/or the eyes and/or horizontally on the forehead and/or in the space between the eyebrows.